535 related articles for article (PubMed ID: 17283114)
21. Targeting farnesoid X receptor for liver and metabolic disorders.
Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
[TBL] [Abstract][Full Text] [Related]
22. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy.
Xing X; Burgermeister E; Geisler F; Einwächter H; Fan L; Hiber M; Rauser S; Walch A; Röcken C; Ebeling M; Wright MB; Schmid RM; Ebert MP
Hepatology; 2009 Mar; 49(3):979-88. PubMed ID: 19072826
[TBL] [Abstract][Full Text] [Related]
23. Potential regulatory role of the farnesoid X receptor in the metabolic syndrome.
Duran-Sandoval D; Cariou B; Fruchart JC; Staels B
Biochimie; 2005 Jan; 87(1):93-8. PubMed ID: 15733743
[TBL] [Abstract][Full Text] [Related]
24. The role of FXR in disorders of bile acid homeostasis.
Eloranta JJ; Kullak-Ublick GA
Physiology (Bethesda); 2008 Oct; 23():286-95. PubMed ID: 18927204
[TBL] [Abstract][Full Text] [Related]
25. Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray.
Higashiyama H; Kinoshita M; Asano S
Acta Histochem; 2008; 110(1):86-93. PubMed ID: 17963822
[TBL] [Abstract][Full Text] [Related]
26. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists.
Zhang S; Liu Q; Wang J; Harnish DC
Biochem Biophys Res Commun; 2009 Feb; 379(2):476-9. PubMed ID: 19118524
[TBL] [Abstract][Full Text] [Related]
27. Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice.
Li G; Kong B; Zhu Y; Zhan L; Williams JA; Tawfik O; Kassel KM; Luyendyk JP; Wang L; Guo GL
Toxicol Appl Pharmacol; 2013 Oct; 272(2):299-305. PubMed ID: 23811326
[TBL] [Abstract][Full Text] [Related]
28. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development.
Maran RR; Thomas A; Roth M; Sheng Z; Esterly N; Pinson D; Gao X; Zhang Y; Ganapathy V; Gonzalez FJ; Guo GL
J Pharmacol Exp Ther; 2009 Feb; 328(2):469-77. PubMed ID: 18981289
[TBL] [Abstract][Full Text] [Related]
29. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids.
Kast HR; Nguyen CM; Sinal CJ; Jones SA; Laffitte BA; Reue K; Gonzalez FJ; Willson TM; Edwards PA
Mol Endocrinol; 2001 Oct; 15(10):1720-8. PubMed ID: 11579204
[TBL] [Abstract][Full Text] [Related]
30. Regulation of carbohydrate metabolism by the farnesoid X receptor.
Stayrook KR; Bramlett KS; Savkur RS; Ficorilli J; Cook T; Christe ME; Michael LF; Burris TP
Endocrinology; 2005 Mar; 146(3):984-91. PubMed ID: 15564327
[TBL] [Abstract][Full Text] [Related]
31. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control.
Kuipers F; Stroeve JH; Caron S; Staels B
Curr Opin Lipidol; 2007 Jun; 18(3):289-97. PubMed ID: 17495603
[TBL] [Abstract][Full Text] [Related]
32. Role of farnesoid X receptor in the enhancement of canalicular bile acid output and excretion of unconjugated bile acids: a mechanism for protection against cholic acid-induced liver toxicity.
Miyata M; Tozawa A; Otsuka H; Nakamura T; Nagata K; Gonzalez FJ; Yamazoe Y
J Pharmacol Exp Ther; 2005 Feb; 312(2):759-66. PubMed ID: 15466244
[TBL] [Abstract][Full Text] [Related]
33. Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor.
Campana G; Pasini P; Roda A; Spampinato S
Biochem Pharmacol; 2005 Jun; 69(12):1755-63. PubMed ID: 15935148
[TBL] [Abstract][Full Text] [Related]
34. The bile acid receptor FXR is a modulator of intestinal innate immunity.
Vavassori P; Mencarelli A; Renga B; Distrutti E; Fiorucci S
J Immunol; 2009 Nov; 183(10):6251-61. PubMed ID: 19864602
[TBL] [Abstract][Full Text] [Related]
35. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.
Wang YD; Chen WD; Wang M; Yu D; Forman BM; Huang W
Hepatology; 2008 Nov; 48(5):1632-43. PubMed ID: 18972444
[TBL] [Abstract][Full Text] [Related]
36. Changes in the pattern of bile acids in the nuclei of rat liver cells during hepatocarcinogenesis.
Mendoza ME; Monte MJ; El-Mir MY; Badia MD; Marin JJ
Clin Sci (Lond); 2002 Feb; 102(2):143-50. PubMed ID: 11834134
[TBL] [Abstract][Full Text] [Related]
37. Loss of orphan receptor small heterodimer partner sensitizes mice to liver injury from obstructive cholestasis.
Park YJ; Qatanani M; Chua SS; LaRey JL; Johnson SA; Watanabe M; Moore DD; Lee YK
Hepatology; 2008 May; 47(5):1578-86. PubMed ID: 18393320
[TBL] [Abstract][Full Text] [Related]
38. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
Modica S; Moschetta A
FEBS Lett; 2006 Oct; 580(23):5492-9. PubMed ID: 16904670
[TBL] [Abstract][Full Text] [Related]
39. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders.
Fiorucci S; Cipriani S; Baldelli F; Mencarelli A
Prog Lipid Res; 2010 Apr; 49(2):171-85. PubMed ID: 19932133
[TBL] [Abstract][Full Text] [Related]
40. Analysis of bile acid-induced regulation of FXR target genes in human liver slices.
Jung D; Elferink MG; Stellaard F; Groothuis GM
Liver Int; 2007 Feb; 27(1):137-44. PubMed ID: 17241392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
